FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company.
FSD Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$2.02|
|52 Week High||CA$1.70|
|52 Week Low||CA$5.25|
|1 Month Change||5.76%|
|3 Month Change||-11.40%|
|1 Year Change||-44.51%|
|3 Year Change||-98.87%|
|5 Year Change||n/a|
|Change since IPO||-91.63%|
Recent News & Updates
Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
|HUGE||CA Pharmaceuticals||CA Market|
Return vs Industry: HUGE underperformed the Canadian Pharmaceuticals industry which returned 29.2% over the past year.
Return vs Market: HUGE underperformed the Canadian Market which returned 29% over the past year.
Stable Share Price: HUGE is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: HUGE's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders.
FSD Pharma Fundamentals Summary
|HUGE fundamental statistics|
Is HUGE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HUGE income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.64|
|Net Profit Margin||0.00%|
How did HUGE perform over the long term?See historical performance and comparison
Is FSD Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HUGE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate HUGE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HUGE is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: HUGE is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HUGE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HUGE is good value based on its PB Ratio (1x) compared to the CA Pharmaceuticals industry average (2.6x).
How is FSD Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as FSD Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has FSD Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HUGE is currently unprofitable.
Growing Profit Margin: HUGE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HUGE is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.
Accelerating Growth: Unable to compare HUGE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HUGE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).
Return on Equity
High ROE: HUGE has a negative Return on Equity (-66.11%), as it is currently unprofitable.
How is FSD Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: HUGE's short term assets ($54.1M) exceed its short term liabilities ($10.0M).
Long Term Liabilities: HUGE's short term assets ($54.1M) exceed its long term liabilities ($61.6K).
Debt to Equity History and Analysis
Debt Level: HUGE's debt to equity ratio (0.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if HUGE's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HUGE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HUGE has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 24.5% each year.
What is FSD Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HUGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HUGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HUGE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HUGE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HUGE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Anthony Durkacz (45 yo)
Mr. Anthony John Durkacz has been Executive Vice President and Director at First Republic Capital Corp., since January 2014. Mr. Durkacz served as the President of Capital Ideas Investor Relations from Jan...
Experienced Management: HUGE's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Experienced Board: HUGE's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 143.4%.
FSD Pharma Inc.'s employee growth, exchange listings and data sources
- Name: FSD Pharma Inc.
- Ticker: HUGE
- Exchange: CNSX
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$72.388m
- Shares outstanding: 35.84m
- Website: https://www.fsdpharma.com
Number of Employees
- FSD Pharma Inc.
- First Canadian Place
- Suite 3400
- M5X 1A4
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 22:16|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.